摘要
心脑血管疾病是糖尿病严重并发症之一,是2型糖尿病患者死亡的首要原因。在糖尿病治疗中,不仅要关注患者的血糖控制水平,还要了解所使用降糖药物对心血管系统的影响,争取为患者带来更大的获益。目前在临床中使用的降糖药物,是否能够在良好控制血糖的同时兼具心血管效应是我们应该关注的问题,特别是新近进入临床使用的肠促胰素类药物的心血管安全性更是值得关注。关于DPP-4抑制剂的心血管安全性的大型前瞻性研究将为DPP-4抑制剂的心血管安全性提供更加充分的循证医学证据。
Cardiovascular disease is one of diabetic complications, is the leading cause of death in patients with type 2 diabetes. The diabetes treatment, should not only focus on the patient＇s level of blood sugar control, to know more about the use of hypoglycemic drugs effects on the cardiovascular system, will bring greater benefit to the patient. In the clinical use of hypoglycemic drug, whether it can protect against cardiovascular complications at the same time in controlling glucose level is more worthy of attention. About the cardiovascular safety of DPP-4 inhibitors, large prospective studies will provide the evidence for the cardiovascular safety of DPP-4 inhibitors.
出处
《药品评价》
CAS
2016年第7期13-17,32,共6页
Drug Evaluation
关键词
糖尿病
2型
二肽基肽酶-4抑制剂
心血管安全性
Type 2 Diabetes
Dipeptide Base Peptidase - 4 Inhibitors
Cardiovascular Safety
